Exosome Diagnostics’ Exosomal RNA Platform Demonstrates Enrichment of Tumor-Specific Gene Changes in Response to Immunotherapy Treatment

Source: Business Wire, November 2015

CAMBRIDGE, Mass.-Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new data demonstrating the novel ability of its proprietary exosomal RNA (exoRNA) technology platform to enrich cancer specific exosomes in order to more precisely determine tumor-specific gene changes in response to immunotherapy treatment.

“The data were presented yesterday, Sunday, November 8, in a late-breaking poster session at the 26th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9 in Boston, Mass. The session was entitled, “Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patients on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response.”……